Sentry Bioconvertible IVC Filter

Sentry Bioconvertible IVC filter designed to bioconvert after the period of transient risk has passed.
Sentry IVC Filter in Filtering Configuration
Sentry IVC Filter in Free-Flowing Configuration
Sentry Bioconvertible IVC filter designed to bioconvert after the period of transient risk has passed.
Sentry IVC Filter in Filtering Configuration
Sentry IVC Filter in Free-Flowing Configuration

Sentry Bioconvertible IVC Filter is designed to provide immediate protection against Pulmonary Embolism (PE) in patients at transient risk of PE.

Key Resources

Explore

Product Description

Sentry is designed to bioconvert following the transient risk period, to leave a patent, unobstructed lumen, eliminating the need for retrieval procedures, as well as reducing the associated risks and complications of conventional long-term filters1.

 

Product Specifications and Sizes

Unique Frame

  • Cylindrical Nitinol frame designed to minimize migration, perforation, embolization, and tilt
  • Self-expanding filter cone formed by 6 arms held centrally by a bioabsorbable filament2
  • Self-centering filtering cone is designed to reduce the risk of tilting and thereby maximizes filtration capacity

Bioconvertible Design 

  • Designed to automatically bioconvert with arms retracting to the IVC wall after the period of transient risk (approximately 60 days)1, providing protection when you need it3-16 
  • Bioconversion process leaves a patent lumen2
  • Eliminates the requirement, cost, and risk associated with IVC filter retrieval
  1. Michael D. Dake, M.D. et al, Presented at VIVA 2017, Las Vegas, NV, September 2017.
  2. Composed of Poly p-dioxanone (PPDO).
  3. Brackenridge. Am. J. Surg. 2011; 201, 209 – 215
  4. Batty. ANZ. J. Surg. 2012; 82, 817–821
  5. Sing. J. Trauma 2016; 60, 732 – 735. 
  6. Coleman. J. Am. Coll. Surg. 2015; 220, 731 – 736. 
  7. Parvizi. J. Arthroplasty 2015; 30: 1,050 – 1,053. 
  8. Bjørnarå. J. Bone Joint Surg. Br. 2006; 88: 386 – 391. 
  9. Arcelus. Thromb. Haemost. 2008; 99: 546 – 551. 
  10. White. Arch. Intern. Med. 1998; 158: 1,525 – 1,531. 
  11. Hope. Am. J. Surg. 2007; 194, 814 – 819. 
  12. Douketis. Arch. Intern. Med. 2000; 160, 3,431 – 3,436. 
  13. Kearon. CHEST J. 2016; 149, 315 – 352. 
  14. Owings. Arch. Surg. 1997; 132: 862 – 867. 
  15. Spencer Netto. Injury 2012; 43: 1,502 – 1,506. 
  16. SooHoo. J. Arthroplasty 2006; 21: 705 – 711. 
  17. Caplin. J. Vasc Interv. Radiol. 2011; 22, 1,499 – 1,506. 
  18. https://btgplc.com/BTG/media/BTG-Sentry/PDFs/IFU-Full-page.pdf

 

Clinical Trial

  • The prospective multicenter SENTRY study demonstrated a high level of safety and effectiveness 
  • The trial established 100% freedom from new symptomatic PEs through 12 months, while typical published rates of symptomatic PEs range from 0.5 – 6%17
  • Eliminates the requirement, cost, and risk associated with IVC filter retrieval
Top